Surgical management of non-small cell lung cancer (NSCLC) invading chest wall is the combination of pulmonary resection, lymphadenectomy and chest wall resection and reconstruction. Hitherto the surgical procedures include combination of thoracotomy and video-assisted thoracoscopic surgery (VATS), thoracotomy, and VATS. The result of the surgery leads to a defect in the chest wall. Therefore, the requirements of the technique and material are relatively high with no consensual standard. This review describes the definitions, indications, materials, prognostic factors, and recent progress in surgical techniques.
Objective To investigate the current development status of chest wall surgery at all levels of hospitals in Sichuan Province, as well as to provide evidence for the promotion of chest wall surgery. Methods We conducted a questionnaire study to investigate chest wall surgery at all levels of hospitals in Sichuan Province and to collect suggestions for chest wall surgery development from thoracic surgeons attending the meeting of the Sichuan International Medical Exchange & Promotion Association from September 2021 to January 2022. Results A total of 128 questionnaires were issued, with 97 (75.8%) of them being valid. According to the survey results, hospitals with grade A secondary or higher in Sichuan Province performed chest wall surgery. Chest wall surgery accounted for 14.3% of thoracic surgery, with 70.4% being chest wall trauma surgeries, 11.6% being chest wall tumor surgeries, 10.5% being chest wall infection surgeries, and 7.5% being chest wall deformity surgeries. Chest wall surgery accounted for 9.3% of thoracic surgery in the grade A tertiary hospitals, primarily for chest wall trauma and tumor; 23.1% in grade B tertiary hospitals, primarily for chest wall trauma and tumor; and 50.7% in grade A secondary hospitals, primarily for chest wall trauma and infection. Totally 96.9% of hospitals supported the establishment of a subspecialty in chest wall surgery. Suggestions for advancing chest wall surgery included: enhancing communication and cooperation (e.g. holding academic conferences, training courses), the establishment of the chest wall surgery association or consortium, and the formulation of regulations and guidelines or consensus, etc. Conclusion Chest wall surgery has been performed at all levels of hospitals in Sichuan Province. The relevant guidelines can be made based on the related academic associations, thus boosting the development of chest wall surgery in the future.
ObjectiveTo explore the effectiveness of the modified designed bilobed latissimus dorsi myocutaneous flap in chest wall reconstruction of locally advanced breast cancer (LABC) patients.MethodsBetween January 2016 and June 2019, 64 unilateral LABC patients were admitted. All patients were female with an average age of 41.3 years (range, 34-50 years). The disease duration ranged from 6 to 32 months (mean, 12.3 months). The diameter of primary tumor ranged from 4.8 to 14.2 cm (mean, 8.59 cm). The size of chest wall defect ranged from 16 cm×15 cm to 20 cm×20 cm after modified radical mastectomy/radical mastectomy. All defects were reconstructed with the modified designed bilobed latissimus dorsi myocutaneous flaps, including 34 cases with antegrade method and 30 cases with retrograde method. The size of skin paddle ranged from 13 cm×5 cm to 17 cm×6 cm. All the donor sites were closed directly.ResultsIn antegrade group, 2 flaps (5.8%, 2/34) showed partial necrosis; in retrograde group, 6 flaps (20%, 6/30) showed partial necrosis, 5 donor sites (16.7%, 5/30) showed partial necrosis; and all of them healed after dressing treatment. The other flaps survived successfully and incisions in donor sites healed by first intention. There was no significant difference in the incidence of partial necrosis between antegrade and retrograde groups (χ2=2.904, P=0.091). The difference in delayed healing rate of donor site between the two groups was significant (P=0.013). The patients were followed up 15-30 months, with an average of 23.1 months. The appearance and texture of the flaps were satisfactory, and only linear scar left in the donor site. No local recurrence was found in all patients. Four patients died of distant metastasis, including 2 cases of liver metastasis, 1 case of brain metastasis, and 1 case of lung metastasis. The average survival time was 22.6 months (range, 20-28 months).ConclusionThe modified designed bilobed latissimus dorsi myocutaneous flap can repair chest wall defect after LABC surgery. Antegrade design of the flap can ensure the blood supply of the flap and reduce the tension of the donor site, decrease the incidence of complications.
Objective To evaluate the biocompatibility and in vivo degradation of novel chest wall prosthesis materials and provide some data for their clinical application. MethodsAccording to the standard for the biological evaluation of the medical devices, several tests were performed to evaluate the tissue toxic effects induced by polydioxanone (Group A), chitosan (Group B), and hydroxyapitite/collagen (Group C),which were tested as component materials of the chest wall prosthesis. In the hemolysis test, 0.2 ml of the anticoagulant rabbit blood was added to the component materials and the normal saline (negative control) and to the distilled water(positive control). Five samples were made in each group. Absorbency was measured and the hemolysis rate was determined. In the acute systemic toxicity test, 20 mice were randomly divided into 4 groups (Groups A, B and C, and the normal saline group, n=5). The leaching liquid (50 ml/kg) was injected through the caudal vein, which was observed at 24, 48 and 72 hours. In the pyrogen test, 12 rabbits were randomly divided into 4 groups (Groups A, B, C and the normal saline group, n=3) the leaching liquid(10 ml/kg) was injected through the ear vein,and the body temperature was recorded within 3 hours. In the in vivo degradable test, the component materials (10 mm×10 mm) were implanted in 12 rabbits at 2, 4, 8, 12, 16 and 24 weeks, respectively, after operation. Two rabbitswere sacrificed for the macroscopic and the microscopic examinations. Results The chest wall component materials had no hemolytic reaction, no acute systemic toxicity, and no pyrogen reaction. The results demonstrated that the implanted materials had only a mild inflammatory reaction during the early days of the grafting, which subsided gradually. There was no tissue denaturation, necrosis or pathological hyperplasia when the prosthesis materials were degraded. Conclusion The degradable materials of the chest wall prosthesis have a good biocompatibility and agreat biological safety though their surgical application still requires a further clinical research.
It is reported in this paper that defect of chest wall of dogs were repaired by hetcrotransplantation of pig bone. The shape of original chest wail were achieved following operation. Histologic study showed that the grown between trabeculae with immersion that method is not only to have same function of other reparing materials,but there is no rejection.